Saluda Medical Quotes 2,080,610 New CDIs Following Barry Regan RSU Conversion on 5 November 2026

Aakashdeep

05 November 2026 03:14 PM AEDT

Saluda Medical Quotes 2,080,610 New CDIs Following Barry Regan RSU Conversion on 5 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Saluda Medical, Inc. (ASX:SLD) has applied for the quotation of 2,080,610 new CHESS Depositary Interests (CDIs) on the ASX, issued on 5 November 2026 following the conversion of 208,061 restricted stock units (RSUs) held by key management personnel member Mr Barry Regan.

Key Points

2,080,610 new SLD CDIs (10:1 ratio, US person prohibited excluding QIB) applied for quotation with an issue date of 5 November 2026
The CDIs were issued following the conversion of 208,061 restricted stock units (SLDAA) held by KMP Mr Barry Regan
The securities were issued for nil cash consideration, with an estimated value per security of AUD $0.000000
Following quotation, total quoted SLD CDIs on issue will stand at 254,104,420

RSU Conversion Details

According to the filing, 208,061 restricted stock units classified under the security code SLDAA were converted into 2,080,610 CDIs under the existing SLD class, reflecting the 10:1 CDI-to-share ratio. The last date on which the convertible securities were converted was 5 November 2026. The filing confirms the conversion was made under an employee incentive scheme. The new CDIs will rank equally in all respects from their issue date with existing issued securities in the same class, according to the company's disclosure.

Key Management Personnel Involvement

The filing identifies Mr Barry Regan as the key management personnel member involved in the RSU conversion, with Mr Barry Regan listed as both the KMP and the registered holder of the 208,061 restricted stock units that were converted. The filing states the consideration provided for the securities was nil, with an estimated value per security of AUD $0.000000. No cash consideration was received in connection with the issue of the new CDIs.

Issued Capital Following Quotation

Following the quotation of the new securities, Saluda Medical's total quoted CDIs on issue will be 254,104,420 under the SLD security code. The company's unquoted securities on issue include 2,526,804 restricted stock units (SLDAA), 1,819,009 options expiring on various dates at various exercise prices (SLDAB), 88,000 warrants expiring 30 June 2036 at USD $17.00 (SLDAE), 263,712 warrants expiring 14 March 2035 at USD $17.00 (SLDAD), and 26 warrants expiring 20 January 2027 at USD $595,540.85 (SLDAC), according to the filing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.